Research Projects & Grants

  • Individual patient program (IPP) use of Trametinib and Dabrafenib for Multisystem Langerhands Cell Histiocytosis, Role: Investigator, (11/2019) Status: Completed

College/University

  • POEM: A PrOspective Registry of Pediatric Cellular Therapy Patients at risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS), Role: Investigator, Duke University, (12/2024 - 12/2025) Status: Approved
  • University of Alabama at Birmingham: National Registry of Pediatric Cancer Patients Diagnosed with COVID-19, Role: PI, University of Alabama at Birmingham, (06/2020) Status: Approved

Federal

  • COG-APEC14B1: project: EveryChild - a registry, eligibility screening, biology and outcome study, Role: Investigator, Children Oncology Group, (09/2024 - 09/2025) Status: Approved
  • COG A031102: a randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus Ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors, Role: Investigator, Children Oncology Group, (09/2024 - 09/2025) Status: Approved
  • COG AAML 1921 / ITCC-054: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, Role: Investigator, Children Oncology Group, (08/2024 - 08/2025) Status: Approved
  • COG AALL1631: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones, Role: Investigator, Children Oncology Group, (07/2024 - 07/2025) Status: Approved
  • COG ACNS1422: A Phase 2 Study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients, Role: Investigator, Children Oncology Group, (06/2024 - 06/2025) Status: Approved
  • TSLP and pediatric leukemia mechanisms and treatment, Role: Investigator, National Cancer Institute/NIH/DHHS, (06/2024 - 06/2025) Status: Approved
  • COG AALL1621: phase 2 study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in children and young adults with relapsed or refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL), Role: Investigator, Children Oncology Group, (06/2024 - 06/2025) Status: Approved
  • COG- AREN03B2 - renal tumors classification, biology and banking study, Role: Investigator, Children Oncology Group, (06/2024 - 06/2025) Status: Approved
  • COG-ANBL00B1 Neuroblastoma biology studies Revised 11/30/2000, Role: Investigator, Children Oncology Group, (03/2025 - 03/2026) Status: Approved
  • COG ARST1431: A randomized phase 3 study of vincristine, dactinomycin, cyclophosphamide (VAC) alternating with vincristine and irinotecan (VI) versus VAC/VI plus temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in patients with intermediate risk (IR) rhabdomyosarcoma (RMS), Role: Investigator, Children Oncology Group, (03/2025 - 03/2026) Status: Approved
  • COG AEWS1221: Randomized phase 3 trial evaluating the addition of the IGF-1R monoclonal antibody ganitumab (AMG 479, NSC# 120449) to multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AAML1331: A phase III study for patients with newly diagnosed acute promyelocytic Leukemia (APL) using arsenic trioxide and all trans-retinoic acid, Role: Investigator, Children Oncology Group, (02/2025 - 02/2026) Status: Approved
  • Children's Oncology Group (COG)-AALL0932: Treatment of patients with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia (ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy), Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG - ACNS0334: A phase III randomized trial for the treatment of newly diagnosed supratentorial PNET and high risk medulloblastoma in children < 36 months old with intensive induction chemotherapy with methotrexate followed by consolidation with stem cell rescue vs. the same therapy without methotrexate, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) - ACNS0831: Phase III randomized trial of post-radiation chemotherapy in patients with newly diagnosed ependymoma ages 1 to 21 years, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) - AEWS1031: A phase III randomized trial of adding vincristine-topotecan-cyclophosphamide to standard chemotherapy in initial treatment of non-metastatic Ewing sarcoma, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG-AAML1031: A phase III randomized trial for patients with de novo AML using Bortezomib (IND# 58443, NSC#681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for patients with high allelic ratio FLT3/ITD, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND #73789, NSC #732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AALL1231: A phase III randomized trial investigating Bortezomib (NSC#681239; IND#58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy), Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) AALL1331: Risk-stratified randomized phase III testing of blinatumomab (IND#117467, NSC#765986) in first relapse of childhood B-Lymphoblastic Leukemia (B-ALL), Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AHOD 1331: randomized phase III study of Brentuximab Vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin Lymphoma (cHL) in children and adolescents, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG AGCT1531: A phase 3 study of active surveillance for low risk and a randomized trial of carboplatin vs. cisplatin for standard risk pediatric and adult patients with germ cell tumors, Role: Investigator, Children Oncology Group, (02/2025 - 02/2026) Status: Approved
  • COG: AALL0434 - Intensified methotrexate, nelarabine (compound 506U78; IND# 52611) and augmented BFM therapy for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-Cell Lymphoblastic Lymphoma, Role: Investigator, Children Oncology Group, (01/2025 - 03/2025) Status: Completed
  • COG-ACNS0332: A study evaluating the efficacy of carboplatin administered concomitantly with radiation and isotretinoin as a pro-apoptotic agent in other than average risk medulloblastoma/PNET patients, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) - AALL0631: A Phase III study of risk directed therapy for infants with acute lymphoblastic leukemia (ALL): Randomization of highest risk infants to intensive chemotherapy +/- FLT3 inhibition (CEP-701, lestaurtinib; IND#76431; NSC#617807), Role: Investigator, Children Oncology Group, (02/2024 - 07/2024) Status: Completed
  • COG- AHOD0831: A non-randomized phase III study of response adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin's Lymphoma, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG-AREN0534: Treatment for patients with bilateral, multicentric, or bilaterally-predisposed unilateral Wilms tumor, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG - ANBL0032 - Phase III randomized study of Chimeric antibody 14.18 (Ch14.18) in high risk Neuroblastoma following Myeloablative Therapy and autologous stem cell rescue, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • COG: AREN0533 - Treatment of newly diagnosed higher risk favorable histology Wilms tumors, Role: Investigator, Children Oncology Group, (01/2025 - 01/2026) Status: Approved
  • Children's Oncology Group (COG) - ALTE05N1: Umbrella long-term follow-up protocol, Role: Investigator, Children Oncology Group, (11/2024 - 11/2025) Status: Approved
  • Sickle Cell Family Planning: A Surveillance, Prevention, & Caring Pathway, Role: Investigator, Maternal and Child Health Bureau/Health Resources and Services Administration/DHHS, (10/2023) Status: Approved
  • COG AAML1531: Risk-stratified therapy for acute myeloid leukemia in Down Syndrome, Role: Investigator, Children Oncology Group, (10/2024 - 10/2025) Status: Approved
  • Maternal Health Research Collaborative for Minority-Serving Institutions, Role: Co-Investigator, Maternal and Child Health Bureau/Health Resources and Services Administration/DHHS, (09/2023 - 09/2026) Status: Awarded
  • COG AOST1421: A phase 2 study of human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 (Dinutuximab, NSC #764038, IND #4308) in combination with sargramostim (GM-CSF) in patients with recurrent osteosarcoma, Role: Investigator, Children Oncology Group, (03/2023 - 03/2024) Status: Completed
  • COG – ARST0332: Risk-Based Treatment for Non-Rhabdomyosarcoma Sort Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age, Role: Investigator, Children Oncology Group, (03/2023 - 02/2024) Status: Completed
  • COG-ANBLOOP3 - A Phase II/III study of the use of intravenous gammaglobulin therapy for patients with neuroblastoma associated opsoclonus-myoclonus-ataxia syndrome, Role: Investigator, Children Oncology Group, (04/2022 - 04/2023) Status: Completed
  • COG: ARST 0531 - Randomized study of vincristine, dactinomycin and cyclophosphamide (VAC) versus VAC alternating with vincristine and ironotecan (VI) for patients with intermediate-risk rhabdomyosarcoma (RMS), Role: Investigator, Children Oncology Group, (04/2022 - 04/2023) Status: Completed
  • COG ACCL 1333 / BMS CV185-155: a phase III randomized, open label, multi-center study of the safety and efficacy of apixaban for thromboembolism prevention versus no systemic anticoagulant prophylaxis during induction chemotherapy in children with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoma (T or B cell) treated with Pegylated (PEG) L-asparaginase, Role: Investigator, Children Oncology Group, (10/2021 - 10/2022) Status: Completed
  • COG ADVL1722 / Eisai E7389-G000-223:A phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS), Role: Investigator, Children Oncology Group, (01/2021 - 01/2022) Status: Completed
  • COG AAML1321/Novartis CAMN107A2203: A multi-center, open label, non-controlled phase II study to evaluate efficacy and safety of oral nilotinib in pediatric patients with newly diagnosed Ph+ chronic myelogenous leukemia (CML) in chronic phase (CP) or with Ph+ CML in CP or accelerated phase (AP) resistance or intolerant to either imatibib or dasatinib, Role: Investigator, Children Oncology Group, (02/2020 - 02/2021) Status: Completed

For Profit Organization

  • COG ADVL1822/ Daiichi Sankyo, Inc. AC220-A-U202: A Phase 1/2, Multicenter, Dose-Escalating study to evaluate the safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Quizartinib administration in combination with re-induction chemotherapy, and as a single-agent continuation therapy, in pediatric relapsed/refractory AML subjects ages 1 month to <18 years (and Young adults ages up to 21 years) with FLT3-ITB mutations, Role: Investigator, Daiichi Sankyo Pharma Development, (04/2025 - 04/2026) Status: Approved
  • A multicenter, prospective, open-label, clinical study to assess the effect of using a new risk score approach to select the most appropriate prophylaxis regimen for reaching a favorable outcome, when hemophilia A patients switch from standard half-life products to damoctocog alfa pegol (Jivi), Role: PI, Bayer Pharmaceuticals, (09/2023 - 01/2025) Status: Completed
  • EAP-Oncoceutics-ONC018: Expanded access to ONC201 for patients with H3 K27M-mutant and/or midline high grade gliomas, Role: Investigator, Oncoceutics, Inc., (10/2022 - 10/2023) Status: Completed
  • Jazz Pharmaceuticals JZP458-201 (COG AALL1931): An open-label, multicenter study of RC-P in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) following hypersensitivity to E. coli-derived asparaginases, Role: Investigator, Jazz Pharmaceuticals, (01/2022 - 01/2023) Status: Completed
  • Pfizer B0661037: A randomized, open-label, active controlled, safety and descriptive efficacy study in pediatric subjects requiring anti-coagulation for the treatment of a venous thromboembolic event, Role: Investigator, Pfizer Inc., U.S. Pharmaceuticals Group, (11/2021 - 11/2022) Status: Completed

Foreign

  • Pediatric blood and marrow transplant consortium (PBMTC) and Canadian Institutes of Health Research (CIHR) - GVHD-1202: Predictive biomarkers for pediatric chronic graft-versus-host disease, Role: Investigator, Canadian Institutes of Health Research, (09/2024 - 09/2025) Status: Approved

Internal

  • A randomized controlled trial comparing daily oral iron administration to every alternate day iron administration in the treatment of iron deficiency anemia in pediatric patients, Role: Investigator, LLU Dept. of Pediatrics, (08/2024) Status: Approved
  • Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 Infection: An Institutional Experience, Role: Investigator, LLU Dept. of Pediatrics, (03/2021) Status: Approved
  • CRM for adults with chronic illnesses outpatient program research study, Role: Investigator, LLU Dept. of Social Work, (07/2019) Status: Approved
  • Quality of Life in Sickle Cell Disease Patients Treated with Red Blood Cell Apheresis, Role: Investigator, LLU Dept. of Medicine, (03/2025) Status: Approved

Non-Profit Organization

  • The National Marrow donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR) - Contribution of a Blood Sample to the National Marrow Donor Program's Research Sample Repository, Role: Investigator, National Marrow Donor Program, (09/2024 - 09/2025) Status: Approved
  • PTCTC ONC1701 (End RAD): A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based on conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative, Role: Investigator, Pediatric Blood and Marrow Transplant Consortium, (06/2024 - 06/2025) Status: Approved
  • NMDP and CIBMTR - Protocol for Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries., Role: Investigator, National Marrow Donor Program, (06/2024 - 06/2025) Status: Approved
  • Improving quality of life for persons with SCD through Resilience and Empowerment (SCD-RE) Program, Role: Investigator, Networking California for Sickle Cell Care, (04/2022) Status: Approved
  • National Marrow Donor Program® (NMDP) - 10-CBA: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications, Role: Investigator, National Marrow Donor Program, (09/2024 - 09/2025) Status: Approved
  • Develop content for key deliverables related to SCD pediatric to adult care transition, Role: PD/PI, National Alliance of Sickle Cell Centers, (08/2024 - 07/2025) Status: Awarded
  • Empowering Transition: A Comprehensive Support Program for Young Adults with Sickle Cell Disease, Role: Investigator, Pfizer and National Alliance of Sickle Cell Centers, (04/2025) Status: Approved
  • Sickle Cell Disease Transition in Care Quality Improvement, Role: Other Significant Contributor, Pfizer and National Alliance of Sickle Cell Centers, (11/2024 - 12/2025) Status: Awarded

State

  • Inland Empire and Desert Region CIRM Community Care Center of Excellence, Role: Sickle Cell Disease Director, California Institute for Regenerative Medicine, (01/2026 - 12/2030) Status: Awarded

Other Research

  • Original project’s as Principal Investigator: IBC-23-011 A Phase 3, single-arm, open-label, multicenter study of the safety and efficacy of dirloctocogene samoparvovec (SPK-8011, adeno-associated viral vector with B-domain deleted human factor VIII gene) in adults with severe or moderately severe hemophilia A (KEYSTONESM 1) Spark Therapeutics, Inc. SM: Clinical Trial Center IBC Approved   Jain, Akshat Gazelle Hb Variant Clinical Accuracy Hemex Health, Inc. SM: Pediatrics Central IRB   Jain, Akshat Provider Perception Survey on curative therapies for Sickle Cell Disease Seek provider insights to assess perceptions of treatment options for patients with sickle cell disease.   SM: Pediatrics Not Human Subject Research   Jain, Akshat American Thrombosis and Hemostasis Network / “ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders” American Thrombosis and Hemostasis Network SM: Pediatrics Central IRB   Jain, Akshat Prospective, Observational, Multicenter Study of Effectiveness of Efanesoctocog Alfa on Long-term Joint Health in Patients with Hemophilia A Sanofi-Aventis U.S., Inc. SM: Pediatrics Central IRB   Jain, Akshat A Phase 3, single-arm, open-label, multicenter study of the safety and efficacy of dirloctocogene samoparvovec (SPK-8011, adeno-associated viral vector with B-domain deleted human factor VIII gene) in adults with severe or moderately severe hemophilia A (KEYSTONESM 1) Spark Therapeutics, Inc. SM: Pediatrics Terminated   Jain, Akshat Evaluation of Access to Care Barriers for Patients and Caregivers with Sickle Cell Disease   SM: Pediatrics Not Human Subject Research   Jain, Akshat A multicenter, prospective, open-label, clinical study to assess the effect of using a new risk score approach to select the most appropriate prophylaxis regimen for reaching a favorable outcome, when hemophilia A patients switch from standard half-life products to damoctocog alfa pegol (Jivi) Bayer Pharmaceuticals SM: Pediatrics Completed   Jain, Akshat Achieving Understanding of the Natural history of sickle cell Trait (AUNT) National Alliance of Sickle Cell Centers SM: Pediatrics Central IRB   Jain, Akshat A Phase 1/2 Open-Label Safety and Dose-Finding Study of BAY 2599023 (DTX201), an Adeno Associated Virus (AAV) hu37-Mediated Gene Transfer of B Domain Deleted Human Factor VIII, in Adults with Severe Hemophilia A Bayer Healthcare SM: Pediatrics Withdrawn   Jain, Akshat American Thrombosis and Hemostasis Network - ATHNdataset   SM: Pediatrics Not Human Subject Research   Jain, Akshat Clinical study to investigate the efficacy, pharmacokinetics, immunogenicity and safety of Wilate in severe Von Willebrand disease patients under the age of 6 years Octapharma SM: Pediatrics Terminated   Jain, Akshat University of Alabama at Birmingham: National Registry of Pediatric Cancer Patients Diagnosed with COVID-19 University of Alabama at Birmingham SM: Pediatrics Approved   Jain, Akshat ATLAS-A/B: A phase 3 study to evaluate the efficacy and safety of Fitusiran in patients with hemophilia A or B, without inhibitory antibodies to factor VIII or IX Sanofi US Services, Inc SM: Pediatrics Terminated   Jain, Akshat ATLAS-PPX: An open-label, multinational, switching study to describe the efficacy and safety of Fitusiran prophylaxis in patients with hemophilia A and B previously receiving factor or bypassing agent prophylaxis Sanofi US Services, Inc SM: Pediatrics Terminated   Jain, Akshat Needs assessment study to evaluate barriers to care for patients with Sickle Cell disease in Inland Empire LLU Dept. of Pediatrics SM: Pediatrics Accepted   Jain, Akshat Bayer healthcare Pharmaceuticals 19429: A Phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an Adeno Associated Virus (AAV) hu37-Mediated gene transfer of B-domain deleted human factor VIII, in adults with severe Hemophilia A Bayer Healthcare SM: Pediatrics Terminated   Jain, Akshat A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with severe hemophilia A   SM: Pediatrics IBC Expired   Jain, Akshat Harnessing Geospatial Mapping to Inform Policy and Overcome Access Barriers to Sickle Cell Centers of Excellence in Southern California Pfizer Pharmaceuticals SM: Pediatrics Pending Sponsor Decision   Jain, Akshat Culturally Tailored, Multidisciplinary Education Initiative for Hemophilia in the Inland Empire Pfizer Pharmaceuticals SM: Pediatrics Pending Sponsor Decision   Jain, Akshat (CDA) IQVIA / Pfizer / Dr. Akshat Jain IQVIA RDS Inc. SM: Pediatrics Fully Executed   Jain, Akshat (CDA) IQVIA RDS, Inc. / Dr. Akshat Jain IQVIA RDS Inc. SM: Pediatrics Fully Executed   Jain, Akshat (CDA) Bayer Healthcare Pharmaceuticals / Dr. Akshat Jain Bayer Pharmaceuticals SM: Pediatrics Fully Executed   Jain, Akshat Gazelle Hb Variant Clinical Accuracy Protocol Hemex Health, Inc. SM: Pediatrics Fully Executed   Jain, Akshat (CDA) Sanofi US Services / Dr. Akshat Jain Sanofi US Services, Inc SM: Pediatrics Fully Executed   Jain, Akshat (CDA) Novo Nordisk Inc. / Dr. Akshat Jain Novo Nordisk Inc. SM: Pediatrics Contract Assigned   Jain, Akshat (CDA) Spark Therapeutics Inc. / Dr. Akshat Jain Spark Therapeutics, Inc. SM: Pediatrics Fully Executed   Jain, Akshat (CDA) Novartis Pharmaceuticals / Dr. Akshat Jain Attachment to MCDA (LLeRA 2230521) Novartis Pharmaceuticals Corporation SM: Pediatrics Fully Executed   Jain, Akshat (CDA) Sanofi US Services Inc. / Dr. Akshat Jain Sanofi US Services, Inc SM: Pediatrics Awarded   Jain, Akshat (CDA) Novartis Pharmaceuticals Corporation / Dr. Akshat Jain Novartis Pharmaceuticals Corporation SM: Pediatrics Awarded   Jain, Akshat Enhancing Awareness and Understanding of Emerging Hemophilia Treatment Options in a Hemophilia Centers of Excellence Pfizer Pharmaceuticals SM: Pediatrics Withdrawn   Jain, Akshat (CDA) Takeda Development / Dr. Akshat Jain Takeda America Research and Development Center Inc SM: Pediatrics Awarded   Jain, Akshat Develop content for key deliverables related to SCD pediatric to adult care transition National Alliance of Sickle Cell Centers SM: Pediatrics Awarded   Jain, Akshat ATHN Transcends American Thrombosis and Hemostasis Network SM: Pediatrics Awarded   Jain, Akshat Prospective, Observational, Multicenter Study of Effectiveness of Efanesoctocog Alfa on Long-term Joint Health in Patients with Hemophilia A Sanofi US Services, Inc SM: Pediatrics Awarded   Jain, Akshat A Phase 3, single-arm, open-label, multicenter study of the safety and efficacy of dirloctocogene samoparvovec (SPK-8011, adeno-associated viral vector with B-domain deleted human factor VIII gene) in adults with severe or moderately severe hemophilia A (KEYSTONESM 1) Syneos Health - CRO Spark Therapeutics, Inc. SM: Pediatrics Closed   Jain, Akshat (CDA) Sanofi US Services, Inc. / Dr. Akshat Jain Sanofi US Services, Inc SM: Pediatrics Awarded   Jain, Akshat Assessment of Silent Stroke in Sickle Cell Patients in Southwestern Nigeria: A US-Africa Collaboration LLU - GRASP SM: Pediatrics Not Funded   Jain, Akshat A multicenter, prospective, open-label, clinical study to assess the effect of using a new risk score approach to select the most appropriate prophylaxis regimen for reaching a favorable outcome, when hemophilia A patients switch from standard half-life products to damoctocog alfa pegol (Jivi) Site Specific Exhibit Protocol #21924 Bayer Healthcare SM: Pediatrics Awarded   Jain, Akshat Achieving Understanding of the Natural history of Sickle Trait (AUNT) National Alliance of Sickle Cell Centers SM: Pediatrics Awarded   Jain, Akshat Inherited Bleeding Disorders and Hemoglobinopathy Program for Children and Young Adults Hope Charities, Inc. SM: Pediatrics Withdrawn   Jain, Akshat Gene and Gene-modified Cell Therapies Medical Education Pfizer Inc., U.S. Pharmaceuticals Group SM: Pediatrics Not Funded   Jain, Akshat (CDA) NASCC / Dr. Akshat Jain National Alliance of Sickle Cell Centers SM: Pediatrics Awarded   Jain, Akshat (CDA) CSL Behring, LLC / Dr. Akshat Jain CSL Behring, LLC SM: Pediatrics Awarded   Jain, Akshat (CDA) Spark Therapeutics / Dr. Akshat Jain Spark Therapeutics, Inc. SM: Pediatrics Awarded   Jain, Akshat (CDA) Sanofi US Services / Dr. Akshat Jain Sanofi US Services, Inc SM: Pediatrics Awarded   Jain, Akshat (CDA) Bayer Healthcare Pharmaceuticals / Dr. Akshat Jain PREDICT Clinical Study Bayer Healthcare SM: Pediatrics Awarded   Jain, Akshat ATHN Data Quality Controls / American Thrombosis and Hemostasis Network Affiliation Agreement American Thrombosis and Hemostasis Network SM: Pediatrics Closed   Jain, Akshat (CDA) Pfizer, Inc. / Dr. Akshat Jain Pfizer Inc., U.S. Pharmaceuticals Group SM: Pediatrics Awarded   Jain, Akshat (CDA) Spark Therapeutics / Dr. Akshat Jain Spark Therapeutics, Inc. SM: Pediatrics Awarded   Jain, Akshat An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor) United BioSource Corporation SM: Pediatrics Awarded   Jain, Akshat Clinical Study to Investigate the Efficacy, Pharmacokinetics, Immunogenicity and Safety of Wilate in Severe Von Wellebrand Disease Patients Under the Age of 6 Years Octapharma SM: Pediatrics Awarded   Jain, Akshat (CDA) Trio Health / Dr. Akshat Jain Trio Health Advisory Group, Inc. SM: Pediatrics Awarded   Jain, Akshat (CDA) Dr. Akshat Jain / Octapharma Octapharma SM: Pediatrics Awarded   Jain, Akshat (CDA) Emory University / Dr. Akshat Jain Emory University SM: Pediatrics Awarded   Jain, Akshat National Registry of Pediatric Cancer Patients Diagnosed with COVID-19 University of Alabama at Birmingham SM: Pediatrics Awarded   Jain, Akshat ATLAS-INH: A Phase 3 study to evaluate the efficacy and safety of fitsurian in patients with hemophilia A or B, without inhibitory antibodies to factor VIII or IX Genzyme Corporation SM: Pediatrics Awarded   Jain, Akshat (CDA) Baxalta US, Inc. / Dr. Akshat Jain Baxalta US, Inc. SM: Pediatrics Awarded   Jain, Akshat (CDA) Bayer Healthcare Pharmaceuticals / Dr. Akshat Jain Bayer Healthcare SM: Pediatrics Awarded   Jain, Akshat ATLAS-PPX: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in patients with hemophilia A and B previously receiving factor or bypassing agent prophylaxis. Genzyme Corporation SM: Pediatrics Awarded   Jain, Akshat Clinical Trials as Specified in the Study Specific Exhibits Bayer Healthcare SM: Pediatrics Closed   Jain, Akshat (CDA) Sanofi / Dr. Akshat Jain Sanofi-Aventis U.S., Inc. SM: Pediatrics Awarded   Jain, Akshat (CDA) Global Blood Therapeutics, Inc. / Dr. Akshat Jain Global Blood Therapeutics, Inc. SM: Pediatrics Awarded   Jain, Akshat (CDA) Bayer HealthCare Pharmaceuticals Inc. / Dr. Akshat Jain Bayer Healthcare SM: Pediatrics Awarded   (06/2023 - 12/2027)
  • Funded Grant : American Thrombosis and Hemostasis Network 2022 Data Grant Principal Investigator (12/2021 - 12/2022)
  • PODCAST :  Amplify Sickle Cell Voices International Topic : Sickle Cell Treatment , Investigation & COVID 19 vaccination a Global outlook Podcast In English & Hindi  (04/2022 - Present)
  • Podcast : Women with Bleeding Disorders: Empathy and Innovation in Patient Care with Dr. Jain (01/2025 - Present)